{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:42:49Z","timestamp":1790131369267,"version":"4.0.1"},"reference-count":68,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,8]]},"abstract":"<jats:p>Checkpoint inhibitors are now widely used in the management of many cancers. Endocrine toxicity is amongst the most common side effects. These endocrinopathies differ from most other immune-related toxicities in frequently being irreversible and rarely requiring cessation of checkpoint inhibitor therapy. This review considers an approach to the presentation and diagnosis of endocrinopathies, compared to classical endocrine diagnosis, suggesting improvements to classification and treatment based on fundamental endocrine principles. These will help to align management with other similar endocrine conditions and standardise the diagnosis and reporting of endocrine toxicity of checkpoint inhibitors to improve both endocrine and oncological care. In particular, the importance of considering any inflammatory phase (such as painful thyroiditis or hypophysitis resulting in the pituitary enlargement), from the endocrine consequences (transient hyperthyroidism followed by hypothyroidism, pan-hypopituitarism or isolated adrenocorticotrophic hormone deficiency), is highlighted. It is also important to consider the potential confounder of exogenous corticosteroids in adrenal suppression.<\/jats:p>","DOI":"10.1530\/ec-22-0513","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T11:40:04Z","timestamp":1678275604000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":29,"title":["Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer"],"prefix":"10.1530","volume":"12","author":[{"given":"Ruth","family":"Percik","sequence":"first","affiliation":[{"name":"Institute of Endocrinology, Diabetes and Metabolism, Sheba Medical Centre, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwin","family":"Criseno","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safwaan","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Young","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-8617","authenticated-orcid":true,"given":"Daniel L","family":"Morganstein","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Chelsea and Westminster Hospital, London, UK"},{"name":"Royal Marsden Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","unstructured":"US Department of Human and Health Services. Common terminology criteria for adverse events (CTCAE). Washington, DC, USA: United States Department of Health and Human Services. (available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf)"},{"key":"bib2","series-title":"Lancet. Oncology","first-page":"905","article-title":"Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis","volume":"22","author":"Percik","year":"2021","unstructured":"Percik RLarkin J & Morganstein DL. Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis. Lancet. Oncology202122905\u2013907. (https:\/\/doi.org\/10.1016\/S1470-2045(2100305-3)"},{"key":"bib3","series-title":"Endocrine Connections","first-page":"G1","article-title":"Society for endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","year":"2018","unstructured":"Higham CE, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, Lorigan P, Morganstein D, Trainer PJ & Society for Endocrinology Clinical Committee. Society for endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocrine Connections20187G1\u2013G7. (https:\/\/doi.org\/10.1530\/EC-18-0068)"},{"key":"bib4","series-title":"European Journal of Endocrinology","first-page":"G1","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition - an ESE clinical practice guideline","volume":"187","year":"2022","unstructured":"Huseb ye ES, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M, Higham CE, Lupi I, Paschou SA, Toth M, Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition - an ESE clinical practice guideline. European Journal of Endocrinology2022187G1\u2013G21. (https:\/\/doi.org\/10.1530\/EJE-22-0689)"},{"key":"bib5","series-title":"Seminars in Immunology","article-title":"Checkpoint blockade toxicities: insights into autoimmunity and treatment","volume":"52","author":"Walsh","year":"2021","unstructured":"Walsh MJ & Dougan M. Checkpoint blockade toxicities: insights into autoimmunity and treatment. Seminars in Immunology202152 101473. (https:\/\/doi.org\/10.1016\/j.smim.2021.101473)"},{"key":"bib6","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3144","article-title":"Programmed cell death-1 (PD-1) inhibitor induced type 1 diabetes mellitus: mini-review","volume":"103","year":"2018","unstructured":"Clotman K, Janssens K, Specenier P, Weets I & De Block CEM. Programmed cell death-1 (PD-1) inhibitor induced type 1 diabetes mellitus: mini-review. Journal of Clinical Endocrinology and Metabolism20181033144\u20133154. (https:\/\/doi.org\/10.1210\/jc.2018-00728)"},{"key":"bib7","series-title":"Journal of Endocrinological Investigation","first-page":"1443","article-title":"Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors","volume":"42","author":"Mazarico","year":"2019","unstructured":"Mazarico ICapel IGimenez-Palop OAlbert LBerges ILuchtenberg FGarcia YFernandez-Morales LADe Pedro VJCaixas A, Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors. Journal of Endocrinological Investigation2019421443\u20131450. (https:\/\/doi.org\/10.1007\/s40618-019-01058-x)"},{"key":"bib8","series-title":"Journal of Clinical Oncology","first-page":"1376","article-title":"Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment","volume":"11","author":"Weijl","year":"1993","unstructured":"Weijl NIVan der Harst DBrand AKooy YVan Luxemburg SSchroder JLentjes EVan Rood JJCleton FJ & Osanto S. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. Journal of Clinical Oncology1993111376\u20131383. (https:\/\/doi.org\/10.1200\/JCO.1993.11.7.1376)"},{"key":"bib9","series-title":"Clinical Medicine","first-page":"417","article-title":"Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?","volume":"20","author":"Kyriacou","year":"2020","unstructured":"Kyriacou AMelson EChen W & Kempegowda P. Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?Clinical Medicine202020417\u2013423. (https:\/\/doi.org\/10.7861\/clinmed.2020-0054)"},{"key":"bib10","series-title":"Endocrine Practice","first-page":"1223","article-title":"Rapid evolution of thyroid dysfunction in patients treated with nivolumab","volume":"23","author":"O'Malley","year":"2017","unstructured":"O'Malley GLee HJParekh SGalsky MDSmith CBFriedlander PYanagisawa RT & Gallagher EJ. Rapid evolution of thyroid dysfunction in patients treated with nivolumab. Endocrine Practice2017231223\u20131231. (https:\/\/doi.org\/10.4158\/EP171832.OR)"},{"key":"bib11","series-title":"Clinical Neurology and Neurosurgery","first-page":"125","article-title":"Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis","volume":"125","author":"Chodakiewitz","year":"2014","unstructured":"Chodakiewitz YBrown SBoxerman JLBrody JM & Rogg JM. Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis. Clinical Neurology and Neurosurgery2014125125\u2013130. (https:\/\/doi.org\/10.1016\/j.clineuro.2014.06.011)"},{"key":"bib12","series-title":"Internal Medicine Journal","first-page":"1066","article-title":"Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series","volume":"45","author":"Lam","year":"2015","unstructured":"Lam TChan MMSweeting ANDe Sousa SMClements ACarlino MSLong GVTonks KChua EKefford RF, Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series. Internal Medicine Journal2015451066\u20131073. (https:\/\/doi.org\/10.1111\/imj.12819)"},{"key":"bib13","series-title":"Pituitary","first-page":"82","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","unstructured":"Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary20161982\u201392. (https:\/\/doi.org\/10.1007\/s11102-015-0671-4)"},{"key":"bib14","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"4078","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","unstructured":"Faje ATSullivan RLawrence DTritos NAFadden RKlibanski A & Nachtigall L. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. Journal of Clinical Endocrinology and Metabolism2014994078\u20134085. (https:\/\/doi.org\/10.1210\/jc.2014-2306)"},{"key":"bib15","series-title":"Pituitary","first-page":"29","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","unstructured":"Dillard TYedinak CGAlumkal J & Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary20101329\u201338. (https:\/\/doi.org\/10.1007\/s11102-009-0193-z)"},{"key":"bib16","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2770","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","unstructured":"Delivanis DAGustafson MPBornschlegl SMerten MMKottschade LWithers SDietz AB & Ryder M. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. Journal of Clinical Endocrinology and Metabolism20171022770\u20132780. (https:\/\/doi.org\/10.1210\/jc.2017-00448)"},{"key":"bib17","series-title":"Future Oncology (London, England)","first-page":"413","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman OElHalawani H & Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncology (London, England)201612413\u2013425. (https:\/\/doi.org\/10.2217\/fon.15.222)"},{"key":"bib18","series-title":"Journal of Endocrinological Investigation","first-page":"195","article-title":"Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH","volume":"44","author":"Siddiqui","year":"2021","unstructured":"Siddiqui MSLai ZMSpain LGreener VTurajlic SLarkin J & Morganstein DL. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH. Journal of Endocrinological Investigation202144195\u2013203. (https:\/\/doi.org\/10.1007\/s40618-020-01297-3)"},{"key":"bib19","series-title":"European Journal of Endocrinology","first-page":"195","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","unstructured":"Albarel FGaudy CCastinetti FCarr\u00e9 TMorange IConte-Devolx BGrob JJ & Brue T. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. European Journal of Endocrinology2015172195\u2013204. (https:\/\/doi.org\/10.1530\/EJE-14-0845)"},{"key":"bib20","series-title":"European Journal of Endocrinology","first-page":"211","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","unstructured":"Faje AReynolds KZubiri LLawrence DCohen JVSullivan RJNachtigall LB & Tritos N. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. European Journal of Endocrinology2019181211\u2013219. (https:\/\/doi.org\/10.1530\/EJE-19-0238)"},{"key":"bib21","series-title":"Endocrinology, Diabetes and Metabolism Case Reports","article-title":"Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases","volume":"2019","author":"Lupi","year":"2019","unstructured":"Lupi IBrancatella ACosottini MViola NLanzolla GSgro DDalmazi GDLatrofa FCaturegli P & Marcocci C. Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases. Endocrinology, Diabetes and Metabolism Case Reports2019201919-0102. (https:\/\/doi.org\/10.1530\/EDM-19-0102)"},{"key":"bib22","series-title":"Endocrine Practice","first-page":"165","article-title":"Immune checkpoint inhibitor-induced adrenalitis and primary adrenal insufficiency: systematic review and optimal management","volume":"27","author":"Shi","year":"2021","unstructured":"Shi YShen MZheng X & Yang T. Immune checkpoint inhibitor-induced adrenalitis and primary adrenal insufficiency: systematic review and optimal management. Endocrine Practice202127165\u2013169. (https:\/\/doi.org\/10.1016\/j.eprac.2020.09.016)"},{"key":"bib23","series-title":"Cureus","article-title":"A rare case of immune-mediated primary adrenal insufficiency with cytotoxic T-lymphocyte Antigen-4 inhibitor ipilimumab in metastatic melanoma of lung and neck of unknown primary","volume":"12","author":"Gaballa","year":"2020","unstructured":"Gaballa SHlaing KMMahler NMoursy S & Ahmed A. A rare case of immune-mediated primary adrenal insufficiency with cytotoxic T-lymphocyte Antigen-4 inhibitor ipilimumab in metastatic melanoma of lung and neck of unknown primary. Cureus202012 e8602. (https:\/\/doi.org\/10.7759\/cureus.8602)"},{"key":"bib24","series-title":"Endocrinology, Diabetes and Metabolism Case Reports","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","author":"Trainer","year":"2016","unstructured":"Trainer HHulse PHigham CETrainer P & Lorigan P. Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinology, Diabetes and Metabolism Case Reports2016201616-0108. (https:\/\/doi.org\/10.1530\/EDM-16-0108)"},{"key":"bib25","series-title":"Endocrinology, Diabetes and Metabolism Case Reports","article-title":"Diabetes insipidus secondary to nivolumab-induced neurohypophysitis and pituitary metastasis","volume":"2021","author":"Fosci","year":"2021","unstructured":"Fosci MPigliaru FSalcuni ASGhiani MCherchi MVCalia MALoviselli A & Velluzzi F. Diabetes insipidus secondary to nivolumab-induced neurohypophysitis and pituitary metastasis. Endocrinology, Diabetes and Metabolism Case Reports20212021 20-0123. (https:\/\/doi.org\/10.1530\/EDM-20-0123)"},{"key":"bib26","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"365","article-title":"Anti\u2013PD-L1 treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","unstructured":"Zhao CTella SHDel Rivero JKommalapati AEbenuwa IGulley JStrauss J & Brownell I. Anti\u2013PD-L1 treatment induced central diabetes insipidus. Journal of Clinical Endocrinology and Metabolism2018103365\u2013369. (https:\/\/doi.org\/10.1210\/jc.2017-01905)"},{"key":"bib27","series-title":"Clinical Medicine","first-page":"371","article-title":"Guidance for the prevention and emergency management of adult patients with adrenal insufficiency","volume":"20","author":"Simpson","year":"2020","unstructured":"Simpson HTomlinson JWass JDean J & Arlt W. Guidance for the prevention and emergency management of adult patients with adrenal insufficiency. Clinical Medicine202020371\u2013378. (https:\/\/doi.org\/10.7861\/clinmed.2019-0324)"},{"key":"bib69","series-title":"Autoimmunity Reviews","first-page":"102454","article-title":"Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors","volume":"19","year":"2020","unstructured":"Percik RShlomai GTirosh ATirosh ALeibowitz-Amit REshet YGreenberg GMerlinsky ABarhod ESteinberg-Silman Y & Sella T.Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors. Autoimmunity Reviews202019102454. https:\/\/doi.org\/10.1016\/j.autrev.2019.102454."},{"key":"bib29","series-title":"Cancer","first-page":"3706","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","unstructured":"Faje ATLawrence DFlaherty KFreedman CFadden RRubin KCohen J & Sullivan RJ. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer20181243706\u20133714. (https:\/\/doi.org\/10.1002\/cncr.31629)"},{"key":"bib30","series-title":"Clinical Cancer Research","first-page":"749","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","unstructured":"Min LHodi FSGiobbie-Hurder AOtt PALuke JJDonahue HDavis MCarroll RS & Kaiser UB. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clinical Cancer Research201521749\u2013755. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2353)"},{"key":"bib31","series-title":"Supportive Care in Cancer","first-page":"3995","article-title":"Emergency ambulatory outpatient management of immune-mediated hypophysitis","volume":"28","author":"Cooksley","year":"2020","unstructured":"Cooksley TKnight TGupta AHigham CLorigan P & Adam S. Emergency ambulatory outpatient management of immune-mediated hypophysitis. Supportive Care in Cancer2020283995\u20133999. (https:\/\/doi.org\/10.1007\/s00520-020-05581-z)"},{"key":"bib32","series-title":"Current Oncology","first-page":"4665","article-title":"Routine screening for central and primary adrenal insufficiency during immune-checkpoint inhibitor therapy: an endocrinology perspective for oncologists","volume":"29","author":"Druce","year":"2022","unstructured":"Druce ITawagi KShaw JLVIbrahim ALochnan H & Ong M. Routine screening for central and primary adrenal insufficiency during immune-checkpoint inhibitor therapy: an endocrinology perspective for oncologists. Current Oncology2022294665\u20134677. (https:\/\/doi.org\/10.3390\/curroncol29070370)"},{"key":"bib33","series-title":"Clinical Endocrinology","first-page":"614","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","unstructured":"Morganstein DLLai ZSpain LDiem SLevine DMace CGore M & Larkin J. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clinical Endocrinology201786614\u2013620. (https:\/\/doi.org\/10.1111\/cen.13297)"},{"key":"bib34","series-title":"European Journal of Endocrinology","first-page":"1","article-title":"Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase","volume":"182","author":"Bai","year":"2020","unstructured":"Bai XChen XWu XHuang YZhuang Y & Lin X. Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase. European Journal of Endocrinology20201821\u20139. (https:\/\/doi.org\/10.1530\/EJE-19-0535)"},{"key":"bib35","series-title":"Thyroid","first-page":"1458","article-title":"Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer","volume":"30","author":"Muir","year":"2020","unstructured":"Muir CAMenzies AMClifton-Bligh R & Tsang VHM. Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer. Thyroid2020301458\u20131469. (https:\/\/doi.org\/10.1089\/thy.2020.0032)"},{"key":"bib36","series-title":"Fundamental and Clinical Pharmacology","first-page":"239","article-title":"Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National pharmacovigilance database","volume":"33","author":"Castinetti","year":"2019","unstructured":"Castinetti F. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National pharmacovigilance database. Fundamental and Clinical Pharmacology201933239\u2013240. (https:\/\/doi.org\/10.1111\/fcp.12453)"},{"key":"bib37","series-title":"Presse Medicale","first-page":"e199","article-title":"Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: retrospective study of 105 patients","volume":"48","author":"Campredon","year":"2019","unstructured":"Campredon PMouly CLusque ABigay-Game LBousquet EMazieres J & Caron P. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: retrospective study of 105 patients. Presse Medicale201948e199\u2013e207. (https:\/\/doi.org\/10.1016\/j.lpm.2018.10.019)"},{"key":"bib38","series-title":"Annals of Oncology","first-page":"583","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","unstructured":"Osorio JCNi AChaft JEPollina RKasler MKStephens DRodriguez CCambridge LRizvi HWolchok JD, Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Annals of Oncology201728583\u2013589. (https:\/\/doi.org\/10.1093\/annonc\/mdw640)"},{"key":"bib39","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"4431","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","unstructured":"de Filette JJansen YSchreuer MEveraert HVelkeniers BNeyns B & Bravenboer B. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. Journal of Clinical Endocrinology and Metabolism20161014431\u20134439. (https:\/\/doi.org\/10.1210\/jc.2016-2300)"},{"key":"bib40","series-title":"Cancer Science","first-page":"3583","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","unstructured":"Kimbara SFujiwara YIwama SOhashi KKuchiba AArima HYamazaki NKitano SYamamoto N & Ohe Y. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Science20181093583\u20133590. (https:\/\/doi.org\/10.1111\/cas.13800)"},{"key":"bib41","series-title":"Clinical Endocrinology","first-page":"258","article-title":"Thyroid disorders in programmed death 1 inhibitor-treated patients: is previous therapy with tyrosine kinase inhibitors a predisposing factor?","volume":"92","author":"Sbardella","year":"2020","unstructured":"Sbardella ETenuta MSirgiovanni GGianfrilli DPozza CVenneri MACortesi EMarchetti PLenzi AGelibter AJ, Thyroid disorders in programmed death 1 inhibitor-treated patients: is previous therapy with tyrosine kinase inhibitors a predisposing factor?Clinical Endocrinology202092258\u2013265. (https:\/\/doi.org\/10.1111\/cen.14135)"},{"key":"bib42","series-title":"Endocrine Connections","first-page":"318","article-title":"Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction","volume":"9","author":"Olsson-Brown","year":"2020","unstructured":"Olsson-Brown ALord RSacco JWagg JColes M & Pirmohamed M. Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction. Endocrine Connections20209318\u2013325. (https:\/\/doi.org\/10.1530\/EC-19-0473)"},{"key":"bib43","series-title":"Cancer Immunology, Immunotherapy","first-page":"679","article-title":"Increased thyroid uptake on 18F-FDG PET\/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies","volume":"70","author":"Frelau","year":"2021","unstructured":"Frelau APalard-Novello XJali EBoussemart LDupuy AJames PDevillers ALe Jeune FEdeline JLesimple T, Increased thyroid uptake on 18F-FDG PET\/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies. Cancer Immunology, Immunotherapy202170679\u2013687. (https:\/\/doi.org\/10.1007\/s00262-020-02712-7)"},{"key":"bib44","series-title":"European Thyroid Journal","first-page":"192","article-title":"Graves\u2019 disease induced by immune checkpoint inhibitors: a case report and review of the literature","volume":"8","author":"Brancatella","year":"2019","unstructured":"Brancatella AViola NBrogioni SMontanelli LSardella CVitti PMarcocci CLupi I & Latrofa F. Graves\u2019 disease induced by immune checkpoint inhibitors: a case report and review of the literature. European Thyroid Journal20198192\u2013195. (https:\/\/doi.org\/10.1159\/000501824)"},{"key":"bib45","series-title":"BMC Endocrine Disorders","first-page":"132","article-title":"New-onset Graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report","volume":"20","author":"Yamada","year":"2020","unstructured":"Yamada HOkajima FOnda TFujimori SEmoto N & Sugihara H. New-onset Graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report. BMC Endocrine Disorders202020132. (https:\/\/doi.org\/10.1186\/s12902-020-00613-5)"},{"key":"bib46","series-title":"Case Reports in Endocrinology","article-title":"Treatment of ipilimumab induced Graves' disease in a patient with metastatic melanoma","volume":"2016","author":"Azmat","year":"2016","unstructured":"Azmat ULiebner DJoehlin-Price AAgrawal A & Nabhan F. Treatment of ipilimumab induced Graves' disease in a patient with metastatic melanoma. Case Reports in Endocrinology20162016 2087525. (https:\/\/doi.org\/10.1155\/2016\/2087525)"},{"key":"bib47","series-title":"Ophthalmic Plastic and Reconstructive Surgery","first-page":"e87","article-title":"Drug-induced graves disease from CTLA-4 receptor suppression","volume":"27","author":"Borodic","year":"2011","unstructured":"Borodic GHinkle DM & Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plastic and Reconstructive Surgery201127e87\u2013e88. (https:\/\/doi.org\/10.1097\/IOP.0b013e3181ef72a1)"},{"key":"bib48","series-title":"Cancers (Basel)","article-title":"Graves' disease during immune checkpoint inhibitor therapy (A case series and literature review)","volume":"13","author":"Peiffert","year":"2021","unstructured":"Peiffert MCugnet-Anceau CDalle SChikh KAssaad SDisse ERaverot GBorson-Chazot F & Abeillon-du Payrat J. Graves' disease during immune checkpoint inhibitor therapy (A case series and literature review). Cancers (Basel)2021131944. (https:\/\/doi.org\/10.3390\/cancers13081944)"},{"key":"bib49","series-title":"Hypothyroidism","year":"2021","unstructured":"NICE.Hypothyroidism. London, UK: NICE National Institute for Health and Care Excellence,2021. (available at: https:\/\/cks.nice.org.uk\/topics\/hypothyroidism\/)"},{"key":"bib50","series-title":"British Medical Journal","first-page":"1185","article-title":"Acute adrenal crisis precipitated by thyroxine","volume":"292","author":"Fonseca","year":"1986","unstructured":"Fonseca VBrown RHochhauser DGinsburg J & Havard CW. Acute adrenal crisis precipitated by thyroxine. British Medical Journal19862921185\u20131186. (https:\/\/doi.org\/10.1136\/bmj.292.6529.1185)"},{"key":"bib51","series-title":"Thyroid","first-page":"496","article-title":"Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from Hashimoto's thyroiditis","volume":"32","author":"Mosaferi","year":"2022","unstructured":"Mosaferi TTsai KSovich SWilhalme HKathuria-Prakash NPraw SSDrakaki AAngell TE & Lechner MG. Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from Hashimoto's thyroiditis. Thyroid202232496\u2013504. (https:\/\/doi.org\/10.1089\/thy.2021.0685)"},{"key":"bib52","series-title":"Journal for ImmunoTherapy of Cancer","first-page":"52","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh","year":"2019","unstructured":"Trinh BSanchez GOHerzig P & Laubli H. Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. Journal for ImmunoTherapy of Cancer2019752. (https:\/\/doi.org\/10.1186\/s40425-019-0528-x)"},{"key":"bib53","series-title":"American Journal of Emergency Medicine","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","unstructured":"Win MAThein KZQdaisat A & Yeung SJ. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. American Journal of Emergency Medicine201735 e1035-1039. (https:\/\/doi.org\/10.1016\/j.ajem.2017.02.048)"},{"key":"bib54","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1581","article-title":"Activating antibodies to the calcium-sensing receptor in immunotherapy-induced hypoparathyroidism","volume":"105","author":"Lupi","year":"2020","unstructured":"Lupi IBrancatella ACetani FLatrofa FKemp EH & Marcocci C. Activating antibodies to the calcium-sensing receptor in immunotherapy-induced hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism20201051581\u20131588. (https:\/\/doi.org\/10.1210\/clinem\/dgaa092)"},{"key":"bib55","series-title":"Journal for ImmunoTherapy of Cancer","article-title":"Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up","volume":"8","author":"Dadu","year":"2020","unstructured":"Dadu RRodgers TETrinh VAKemp EHCubb TDPatel SSimon JMBurton EM & Tawbi H. Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. Journal for ImmunoTherapy of Cancer20208e000687. (https:\/\/doi.org\/10.1136\/jitc-2020-000687)"},{"key":"bib56","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"550","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","unstructured":"Piranavan PLi YBrown EKemp EH & Trivedi N. Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. Journal of Clinical Endocrinology and Metabolism2019104550\u2013556. (https:\/\/doi.org\/10.1210\/jc.2018-01151)"},{"key":"bib57","series-title":"European Journal of Endocrinology","first-page":"G1","article-title":"European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","unstructured":"Bollerslev JRejnmark LMarcocci CShoback DMSitges-Serra Avan Biesen WDekkers OM & European Society of Endocrinology. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. European Journal of Endocrinology2015173G1\u2013G20. (https:\/\/doi.org\/10.1530\/EJE-15-0628)"},{"key":"bib58","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"5499","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from Type 1 diabetes","volume":"104","author":"Tsang","year":"2019","unstructured":"Tsang VHMMcGrath RTClifton-Bligh RJScolyer RAJakrot VGuminski ADLong GV & Menzies AM. Checkpoint inhibitor-associated autoimmune diabetes is distinct from Type 1 diabetes. Journal of Clinical Endocrinology and Metabolism20191045499\u20135506. (https:\/\/doi.org\/10.1210\/jc.2019-00423)"},{"key":"bib59","series-title":"Acta Diabetologica","first-page":"441","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2019","unstructured":"Marchand LThivolet ADalle SChikh KReffet SVouillarmet JFabien NCugnet-Anceau C & Thivolet C. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype. Acta Diabetologica201956441\u2013448. (https:\/\/doi.org\/10.1007\/s00592-018-1234-8)"},{"key":"bib60","series-title":"Diabetic Medicine","first-page":"1283","article-title":"Diabetes associated with immune checkpoint inhibition: presentation and management challenges","volume":"35","author":"Galligan","year":"2018","unstructured":"Galligan AXu WFourlanos SNankervis AChiang CMant AMParente PRischin DKrishnamurthy BSandhu S, Diabetes associated with immune checkpoint inhibition: presentation and management challenges. Diabetic Medicine2018351283\u20131290. (https:\/\/doi.org\/10.1111\/dme.13762)"},{"key":"bib61","series-title":"BMJ Case Reports","article-title":"Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies","volume":"2017","author":"Way","year":"2017","unstructured":"Way JDrakaki ADrexler A & Freeby M. Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies. BMJ Case Reports20172017bcr-2017-220415. (https:\/\/doi.org\/10.1136\/bcr-2017-220415)"},{"key":"bib62","series-title":"Therapie","first-page":"695","article-title":"Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: a French pharmacovigilance study","volume":"76","author":"Bastin","year":"2021","unstructured":"Bastin MAllouchery MSassier MRouby FEftekhari PLebrun-Vignes BAndreelli F & Bihan K. Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: a French pharmacovigilance study. Therapie202176695\u2013703. (https:\/\/doi.org\/10.1016\/j.therap.2021.03.004)"},{"key":"bib63","series-title":"Frontiers in Endocrinology (Lausanne)","first-page":"14","article-title":"Immune checkpoint inhibitor-induced diabetic ketoacidosis: a report of four cases and literature review","volume":"11","author":"Hong","year":"2020","unstructured":"Hong ARYoon JHKim HK & Kang HC. Immune checkpoint inhibitor-induced diabetic ketoacidosis: a report of four cases and literature review. Frontiers in Endocrinology (Lausanne)20201114. (https:\/\/doi.org\/10.3389\/fendo.2020.00014)"},{"key":"bib64","series-title":"Clinical Medicine","first-page":"163","article-title":"Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma","volume":"20","author":"Agarwal","year":"2020","unstructured":"Agarwal KYousaf N & Morganstein D. Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma. Clinical Medicine202020163\u2013168. (https:\/\/doi.org\/10.7861\/clinmed.2018-0440)"},{"key":"bib65","series-title":"Diabetic Medicine","first-page":"e15053","article-title":"Hyperglycaemia following immune checkpoint inhibitor therapy\u2014incidence, aetiology and assessment","volume":"40","author":"Mulla","year":"2023","unstructured":"Mulla KFarag SMoore BMatharu SYoung KLarkin JPopat S & Morganstein DL. Hyperglycaemia following immune checkpoint inhibitor therapy\u2014incidence, aetiology and assessment. Diabetic Medicine202340e15053. (https:\/\/doi.org\/10.1111\/dme.15053)"},{"key":"bib66","series-title":"Diabetic Medicine","article-title":"Board R and joint British diabetes society for inpatient care UKCB. A guideline for the outpatient management of glycaemic control in people with cancer","volume":"2022","author":"Joharatnam-Hogan","year":"2021","unstructured":"Joharatnam-Hogan NChambers P & Dhatariya K. Board R and joint British diabetes society for inpatient care UKCB. A guideline for the outpatient management of glycaemic control in people with cancer. Diabetic Medicine20212022 e14636. (https:\/\/doi.org\/10.1111\/dme.14636)"},{"key":"bib67","series-title":"Diabetic Medicine","first-page":"1011","article-title":"Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group","volume":"35","author":"Roberts","year":"2018","unstructured":"Roberts AJames JDhatariya K & Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabetic Medicine2018351011\u20131017. (https:\/\/doi.org\/10.1111\/dme.13675)"},{"issue":"Supplement 4","key":"bib68","series-title":"Annals of Oncology","first-page":"iv119","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","unstructured":"Haanen JBAGCarbonnel FRobert CKerr KMPeters SLarkin JJordan K & ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology201728(Supplement 4) iv119\u2013iv142. (https:\/\/doi.org\/10.1093\/annonc\/mdx225)"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/12\/5\/EC-22-0513.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/12\/5\/EC-22-0513.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/12\/5\/EC-22-0513.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:02Z","timestamp":1784555162000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/1144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":68,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1530\/ec-22-0513","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]}}}